242 related articles for article (PubMed ID: 35344689)
1. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
[TBL] [Abstract][Full Text] [Related]
2. Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement.
Murray D; Kumar SK; Kyle RA; Dispenzieri A; Dasari S; Larson DR; Vachon C; Cerhan JR; Rajkumar SV
Blood Cancer J; 2019 Dec; 9(12):102. PubMed ID: 31836698
[TBL] [Abstract][Full Text] [Related]
3. Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.
Lee DJ; El-Khoury H; Tramontano AC; Alberge JB; Perry J; Davis MI; Horowitz E; Redd R; Sakrikar D; Barnidge D; Perkins MC; Harding S; Mucci L; Rebbeck TR; Ghobrial IM; Marinac CR
Blood Adv; 2024 Apr; 8(7):1737-1746. PubMed ID: 38212245
[TBL] [Abstract][Full Text] [Related]
4. Disease associations with monoclonal gammopathy of undetermined significance can only be evaluated using screened cohorts: results from the population-based iStopMM study.
Sigurbergsdóttir AÝ; Rögnvaldsson S; Thorsteinsdóttir S; Sverrisdóttir I; Sigurðardóttir GÁ; Viðarsson B; Önundarson PT; Agnarsson BA; Sigurðardóttir M; Þorsteinsdóttir I; Ólafsson Í; Þórðardóttir ÁR; Gíslason GK; Ólafsson A; Hultcrantz M; Durie BGM; Harding S; Landgren O; Löve TJ; Kristinsson SY
Haematologica; 2023 Dec; 108(12):3392-3398. PubMed ID: 37439374
[TBL] [Abstract][Full Text] [Related]
5. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method.
Vachon CM; Murray J; Allmer C; Larson D; Norman AD; Sinnwell JP; Dispenzieri A; Kleinstern G; Visram A; Kyle RA; Rajkumar SV; Slager SL; Kumar SK; Murray DL
Blood Adv; 2022 Jun; 6(12):3746-3750. PubMed ID: 35316833
[TBL] [Abstract][Full Text] [Related]
7. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.
Landgren O; Graubard BI; Katzmann JA; Kyle RA; Ahmadizadeh I; Clark R; Kumar SK; Dispenzieri A; Greenberg AJ; Therneau TM; Melton LJ; Caporaso N; Korde N; Roschewski M; Costello R; McQuillan GM; Rajkumar SV
Leukemia; 2014 Jul; 28(7):1537-42. PubMed ID: 24441287
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan.
Iwanaga M; Tagawa M; Tsukasaki K; Kamihira S; Tomonaga M
Mayo Clin Proc; 2007 Dec; 82(12):1474-9. PubMed ID: 18053454
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of monoclonal gammopathy in Morocco - A hospital-based study.
Ouzzif Z; Doghmi K; Messaoudi N; Bouhsain S; El Machtani S; Biaz A; Rachid A; Dami A; Bezza A; El Maataoui A
Cancer Rep (Hoboken); 2023 May; 6(5):e1814. PubMed ID: 36999311
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.
Vachon CM; Kyle RA; Therneau TM; Foreman BJ; Larson DR; Colby CL; Phelps TK; Dispenzieri A; Kumar SK; Katzmann JA; Rajkumar SV
Blood; 2009 Jul; 114(4):785-90. PubMed ID: 19179466
[TBL] [Abstract][Full Text] [Related]
12. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study.
Gupta R; Dahiya M; Kumar L; Shekhar V; Sharma A; Ramakrishnan L; Sharma OD; Begum A
Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):e345-e350. PubMed ID: 29980412
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men.
Cicero KI; Joffe M; Patel M; Chiuzan C; Pentz A; Ruff P; Lentzsch S; Leng S; Jacobson JS; Rebbeck TR; Neugut AI
Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2192-2198. PubMed ID: 36126958
[TBL] [Abstract][Full Text] [Related]
15. Retrospective study of monoclonal gammopathies detected in the clinical laboratory of a Spanish healthcare district: 14-year series.
Bergón E; Miravalles E
Clin Chem Lab Med; 2007; 45(2):190-6. PubMed ID: 17311507
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy in a tertiary referral hospital.
Tamimi W; Alaskar A; Alassiri M; Alsaeed W; Alarifi SA; Alenzi FQ; Jawdat D
Clin Biochem; 2010 Jun; 43(9):709-13. PubMed ID: 20206156
[TBL] [Abstract][Full Text] [Related]
17. Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.
Chang SH; Luo S; Thomas TS; O'Brian KK; Colditz GA; Carlsson NP; Carson KR
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040690
[TBL] [Abstract][Full Text] [Related]
18. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
19. Direct Mass Spectrometry-Based Detection and Antibody Sequencing of Monoclonal Gammopathy of Undetermined Significance from Patient Serum: A Case Study.
Peng W; den Boer MA; Tamara S; Mokiem NJ; van der Lans SPA; Bondt A; Schulte D; Haas PJ; Minnema MC; Rooijakkers SHM; van Zuilen AD; Heck AJR; Snijder J
J Proteome Res; 2023 Sep; 22(9):3022-3028. PubMed ID: 37499263
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
